EPAS1 and glioblastoma: Furthermore, as our results indicate a modest additive effect with temozolomide in cell killing and complementary influences on CSC differentiation status, combination therapies that combine chemotherapeutics with HIF-2a silencing or inhibition are an attractive avenue in the pursuit of a therapy that can eradicate the CSCs that drive recurrence of malignant cancers such as glioblastoma[33,34].